LOCHOLEST LIGHT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOCHOLEST LIGHT (LOCHOLEST LIGHT).
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
| Metabolism | Not metabolized; excreted unchanged in feces as the bile acid-resin complex. |
| Excretion | Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites). |
| Half-life | Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.5-0.7 L/kg; extensive distribution into extravascular tissues, including the liver, which is the primary site of action. |
| Bioavailability | Oral bioavailability is low (approximately 5-10%) due to extensive first-pass metabolism in the liver and gut wall; food increases absorption slightly (no dosage adjustment required). |
| Onset of Action | Reduction in LDL-C begins within 1-2 weeks of oral administration; significant reductions (15-20%) are typically seen by 4 weeks. |
| Duration of Action | LDL-C lowering persists for the duration of therapy; upon discontinuation, cholesterol levels gradually return to baseline over several weeks. No clinically relevant duration beyond dosing interval. |
| Molecular Weight | 476.61 |
LOCHOLEST LIGHT is not a recognized drug name. No data available.
| Dosage form | POWDER |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Contraindicated due to risk of fetal skeletal malformations from interference with hedgehog signaling pathway. |
| 2nd trimester | Contraindicated due to continued risk of fetal skeletal and neurological development disruption. |
| 3rd trimester | Contraindicated due to risk of premature closure of fetal epiphyseal growth plates and potential neurological effects. |
Clinical note
Comprehensive clinical and safety monograph for LOCHOLEST LIGHT (LOCHOLEST LIGHT).
| Placental transfer | Known to cross placenta based on animal studies and human case reports; molecular weight and lipophilicity favor transfer. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing, considering importance to mother. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
PregnancyWomen of childbearing potential not using effective contraceptionHypersensitivity to atorvastatin or any componentActive liver disease or unexplained persistent transaminase elevations
| Precautions | May cause hypertriglyceridemia; monitor triglycerides. Risk of bleeding due to vitamin K deficiency with long-term use. May reduce absorption of fat-soluble vitamins (A, D, E, K). Can cause fecal impaction; use with caution in constipation-prone patients. May bind other drugs; separate administration by at least 4 hours. |
| Food/Dietary | Cholestyramine binds to bile acids and can interfere with absorption of fat-soluble vitamins (A, D, E, K). Patients should consume a diet rich in these vitamins or consider supplementation. High-fiber foods may aid in reducing constipation. Avoid excessive intake of high-fat foods as they may worsen hypertriglyceridemia. |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) - Highest risk; avoid breastfeeding. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documented human fetal adverse effects. Overall, use only if clearly needed. |
| Fetal Monitoring | Monitor maternal lipid levels, liver function tests, and fetal growth via ultrasound if used in pregnancy. |
| Fertility Effects | No known effect on fertility in animal studies. Human data insufficient. |
| Clinical Pearls | Locholest Light (cholestyramine) is a bile acid sequestrant used for hyperlipidemia. Monitor for decreased absorption of fat-soluble vitamins (A, D, E, K) and consider supplementation. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. May increase triglyceride levels; avoid in patients with hypertriglyceridemia above 400 mg/dL. Can cause constipation; ensure adequate fluid and fiber intake. |
| Patient Advice | Take cholestyramine exactly as prescribed, usually mixed with at least 4-6 ounces of fluid. · Do not take the powder dry; always mix with water, juice, or milk to avoid choking. · Take other medications at least 1 hour before or 4-6 hours after cholestyramine. · Drink plenty of fluids and eat high-fiber foods to prevent constipation. · Report unusual bleeding, bruising, or dark stools as signs of vitamin K deficiency. · This medication may increase triglyceride levels; monitor blood tests as directed. |